SAN ANTONIO, July 26, 2016 /PRNewswire/ — Espada Dermatology™, Inc. (Espada) announced today the recent purchase of the GlyDerm line of skin care products from Lautus Pharmaceuticals, LLC. Espada is a wholly-owned subsidiary of Mission Pharmacal Company (Mission) and adds breadth to Mission’s established line of dermatological drug products.

Prior to this acquisition, Mission offered prescription dermatological products solely through Mission Dermatology and the Brava Pharma Sales Group. The products these two respective units offer will remain in place and are used to relieve dry, itchy skin, acne, and dermatitis. By adding Espada as a consumer product entity focusing on esthetic dermatology to the total Mission dermatological portfolio, the company plans to initiate an educational effort, as well as market growth strategies to benefit both healthcare providers and consumers.

“This acquisition demonstrates Mission’s focus and commitment to dermatology and skin health,” says Terry Herring, President, Commercial Operations of Mission. He further adds, “We look forward to partnering with healthcare providers in the growth and expansion of esthetic dermatology and improving the care and treatment of patients. We are excited to offer GlyDerm, a product with a proven track record in esthetic dermatology and skin health.”

GlyDerm skincare products deliver gentle, effective, full-potency glycolic acid to the skin over time by utilizing a unique esterification process. This proprietary process allows for a time-released delivery of glycolic acid that works gently to reduce the signs of aging and photo damage. The product extends Mission’s dermatology line to include the newest advances in anti-aging formulation and improve the customer experience by deploying a highly trained sales force.

To support Espada’s acquisition, Trey Schutz has joined the company as Vice President, General Manager, Mission Dermatology. As a proven marketing executive with more than 20 years of progressive experience focusing on new product development Schutz will oversee a product portfolio of dermatology products that have both a prescription and consumer focus. Working with Schutz on the prescription side of Mission Dermatology will be David Kinnard, who will continue to oversee the sales and marketing efforts for the Mission and Brava Dermatology teams. Specific to Espada and the consumer side of Mission Dermatology, Schutz will work with Steve Bosacki, Executive Director, Dermatology Consumer Esthetics.

“I am pleased to join Mission as we further expand the company’s dermatological offerings,” notes Schutz. “It is also exciting to have this talented team of existing Mission Dermatology experts and new leaders with their own pharmaceutical experiences. Together we believe the addition of Espada and the GlyDerm consumer product line to what Mission Dermatology already offers in terms of high quality prescription products will ultimately offer new levels of patient care and combined success. Our intent is to bring our collective experiences and long-lasting physician relationships to strengthen the program and its commitment to skin health innovation.”

About Espada Dermatology, Inc.
Espada Dermatology, Inc. is an independent, U.S.-based esthetic dermatology company supplying the GlyDerm line of quality skin care products to consumers through physician offices to help patients improve overall skin health. For more information about GlyDerm, please visit GlyDermUSA.com.

Espada Dermatology, Inc. is a part of the Mission family of companies that also includes BioComp Pharma, Inc., a generic drug distributor; Alamo Pharma Services, Inc., a specialized contract sales organization; ProSolus, Inc., a transdermal drug developer and manufacturer and BexR Logistix, LLC, a logistics and fulfillment company. To learn more, please visit missionpharmacal.com.

Photo – http://photos.prnewswire.com/prnh/20160726/393128

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mission-pharmacal-expands-dermatology-commitment-with-the-acquisition-of-glyderm-300304279.html

SOURCE Mission Pharmacal Company